Equity

Summit Therapeutics Inc. (SMMT) Stock — Today's Move

▼ -6.27%

$14.50

$-0.97 today

SMMT is down 6.27% today. Volume is 4.76M vs a 30-day average of 6.75M (0.71x).

Day High

$15.62

Day Low

$14.37

Open

$15.49

Prev Close

$15.47

Volume

4.76M

Avg Vol (30d)

6.75M

52-Wk High

$29.23

52-Wk Low

$12.07

Sector

—

Today's Move

-6.27%

Next Earnings

Wed, Nov 11

Summit Therapeutics Inc. is scheduled to report earnings Wed, Nov 11, 2026. Analysts expect EPS of $-0.29 on revenue of about $68.0K. Stocks often move sharply on earnings day.

52-wk low $12.0752-wk high $29.23

SMMT is 14% of the way from its 52-week low to its high.

Indicators:

Close price · volume bars (dashed line = average volume) · news that day (2M–1Y) — hover or tap the chart. Indicators are for education, not trading advice.

Why is SMMT moving today?

Yahoo· Oct 25, 3:52pm

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

MIAMI, October 25, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating…

Yahoo· Oct 24, 1:26am

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platf…

Yahoo· Oct 23, 8:37pm

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

MIAMI & SEOUL, South Korea, October 23, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Luni…

Yahoo· Oct 22, 1:49pm

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.

Yahoo· Oct 22, 10:00am

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

MIAMI, October 22, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medic…

Related Movers

▼ -48.36%

XP Inc.

Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Session

$15.71 -$14.71

Vol: 132.61M (13.2x avg) Financial Services

INTR

▼ -34.91%

Inter & Co. Inc.

S&P Index Addition Could Change The Case For Inter (INTR) Stock

$4.68 -$2.51

Vol: 55.63M (7.3x avg) Banking

BBD

▼ -28.01%

Banco Bradesco Sa

Most Active Stocks on Oct. 26: RCT, NU and BBD Top Volume

$2.93 -$1.14

Vol: 204.08M (5.3x avg) Banking

SBS

▼ -26.09%

Companhia de saneamento Basico

$4.73 -$1.67

Vol: 54.76M (5.2x avg) Utilities

FAQ — SMMT

Why is SMMT moving today?

SMMT is down 6.27% in the current session. Scroll to the news section below to see the most recent headlines and catalysts driving the move.

Is Summit Therapeutics Inc. a good stock to buy today?

WeeklyTrader.io does not provide financial advice. Always verify catalysts, assess risk, and conduct your own research before making any investment decision.

What is SMMT's average volume?

Average volume for SMMT is approximately 6.75M shares per day based on the trailing 30 sessions.

Where can I see more stocks like SMMT?

Visit the sector filter on the gainers and losers pages to see related movers.